Slide 1: Capital Market Presentation – H1'21
Capital Market Presentation – H1’21 August 2021 1
Slide 2: Disclaimer
Disclaimer - The objective of this presentation is to present the activity of NRGene Technologies Ltd (the “Company”) and to provide preliminary and basic information regarding its activities. In accessing this presentation, you agree to be bound by the following terms and conditions. - This present
Slide 3: Agenda
Agenda - Executive summary - Agricultural and food industry value chain improvement - Business model expansion and focus - IP development agreements in return for royalties - Financial results highlights– H1, 2021 - Summary 3
Slide 4: Executive Summary
Executive Summary Accelerating Seed and Plant Breeding Worldwide through Artificial Intelligence 2010 Company Founded 2015 Products Launched 2021 $30 million (gross) were raised through an IPO on the Tel Aviv Stock Exchange +100 Customers, among them leading companies in the seed, food & beverage, p
Slide 5: Executive Summary - Continued
Executive Summary - Continued 1. IP development in return for royalties − Identifying business opportunities to develop new elite varieties − Turnaround time from development to commercialization: 2 to 5 years − Potential revenues of millions of dollars per project Example - Resistance to the ToBRFV
Slide 6: Executive Summary - Continued
Executive Summary - Continued 2. Development and commercialization of DNA tests (genotyping solutions) in plants and animals: - Development of targeted DNA panels for tests - Establishment of genotyping lab in Canada - Amassed revenues from the lab are estimated at $20 million between 2021-2025. Exa
Slide 7: Social and Environmental Value Creation
Social and Environmental Value Creation NRGene contributes to each step in the agricultural value chain, while focusing on sustainable food production and reduction of the environmental footprint Sustainable Agriculture Clean Vitamin Alternative Energy Rich Foods Proteins Flavor Protein Rich Improve
Slide 8: Agricultural and Food Industry Value Chain Improvement
Agricultural and Food Industry Value Chain Improvement - Shorter and faster processes of elite varieties’ development using NRGene’s technology - Higher revenues throughout the entire value chain - NRGene shares the risks with its business partners Example: ToBRFV resistant tomato varieties impact o
Slide 9: Business Model Expansion and Focus
Business Model Expansion and Focus H12021 H1 2020 VS H1 2021 Long term & ~60% of new agreements recurring ~90% of new agreements agreements IP 0 signed agreements development, 4 signed commercial agreements (ToBRFV Resistance) 0 signed agreements for new in return for Alternative protein project – p
Slide 10: Business Model Expansion and Focus
Business Model Expansion and Focus 2020 VS 2021 and forward Recuring agreements/multi-year subscription Multi-year subscription Main revenue Genotyping tests and data creation One-time genomic analysis services model Royalties from IP development Main revenue R&D budget and seed production of breedi
Slide 11: IP Development Agreements in Return for Royalties
IP Development Agreements in Return for Royalties Expected development and implementation by customers Project 2021 2022 2023 2024 2025 2030 Maize, chili and rice breeding Commercialization and implementation Royalties for the Indian market Herbs breeding program Commercialization and implementation
Slide 12: IP Development Agreements in Return for Royalties
IP Development Agreements in Return for Royalties Business Potential Expected Revenue Potential Target Expected Commercialization Expected Revenue From Royalties Project Market Size Development Time Status* From Royalties Throughout (Seeds/Year) Project’s Lifetime In commercialization Disease resist
Slide 13: Financial Results Highlights (Thousands US Dollars)
Financial Results Highlights* (Thousands US Dollars) In thousands dollars H1-2020 H2-2021 FY- 2020 Comments Focus on long-term and recurring projects (DNA tests and IP Revenues 2,809 2,148 7,035 development), gradually replacing one-time genomic analysis services and the impact of COVID-19 Decrease
Slide 14: Summary
Summary 2022 Forward looking: Since the IPO completion, the company has signed deals in various crops: Tomato Canola Cannabis & Hemp Shrimp Guayule Coffee Maize The company estimates that additional substantial agreements will be signed by the end of 2021 Expansion: Opening of new office
Slide 15: Thank You
nrgene THANK YOU ©